HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic

Simula, Elena Rita; Manca, Maria Antonietta; Jasemi, Seyedesomaye; Uzzau, Sergio; Rubino, Salvatore; Manchia, Pierangela; Bitti, Angela; Palermo, Mario; Sechi, Leonardo Antonio

doi:10.3390/microorganisms8121993

Cited by 31 publications

(34 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This status had no influence on the antibody response against SARS-CoV-2 [42]. Similarly, the findings of Simula et al (2020) showed that antibodies against NL63 have the potential to cross-react against SARS-CoV-2 spike protein [43]. The preexisting humoral responses against SARS-CoV-2 were also reported to be against N and spike proteins [44,45].…”

Section: Pre-existing Antibodies In the Individuals Against Sars-cov-2 In The Absence Of Virus Infectionmentioning

confidence: 81%

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Muthumani

Jeong

et al. 2021

transl med commun

View full text Add to dashboard Cite

The causative agent of the ongoing pandemic in the world is SARS-CoV-2. The research on SARS-CoV-2 has progressed with lightning speed on various fronts, including clinical research and treatment, virology, epidemiology, drug development, and vaccine research. Recent studies reported that sera from healthy individuals, who were confirmed negative for SARS-CoV-2 by RT-PCR method, tested positive for antibodies against spike and nucleocapsid proteins of SARS-CoV-2. Further, such antibodies also exhibited neutralizing activity against the virus. These observations have prompted us to prepare a commentary on this topic. While the preexisting antibodies are likely to protect against SARS-CoV-2 infection, they may also complicate serological testing results. Another unknown is the influence of preexisting antibodies on immune responses in individuals receiving vaccines against SARS-CoV-2. The commentary identifies the potential limitations with the serological tests based on spike and nucleocapsid proteins as these tests may overestimate the seroprevalence due to cross-reactive antibodies. The inclusion of tests specific to SARS-CoV-2 (such as RBD of spike protein) could overcome these limitations.

show abstract

Section: Pre-existing Antibodies In the Individuals Against Sars-cov-2 In The Absence Of Virus Infectionmentioning

confidence: 81%

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Muthumani

Jeong

et al. 2021

transl med commun

View full text Add to dashboard Cite

show abstract

“…In the context of the COVID-19 pandemic, there are a growing number of studies on the seroprevalence of antibodies to HCoV-NL63 [8,17,18]. Most have utilised serological assays that test for recognition of viral peptides that may not reflect functional antibody (neutralising) activity, making comparisons to our study difficult.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia

Lynch

Subbarao

Mahanty

et al. 2021

Viruses

View full text Add to dashboard Cite

The COVID-19 pandemic has highlighted the importance of understanding the immune response to seasonal human coronavirus (HCoV) infections such as HCoV-NL63, how existing neutralising antibodies to HCoV may modulate responses to SARS-CoV-2 infection, and the utility of seasonal HCoV as human challenge models. Therefore, in this study we quantified HCoV-NL63 neutralising antibody titres in a healthy adult population using plasma from 100 blood donors in Australia. A microneutralisation assay was performed with plasma diluted from 1:10 to 1:160 and tested with the HCoV-NL63 Amsterdam-1 strain. Neutralising antibodies were detected in 71% of the plasma samples, with a median geometric mean titre of 14. This titre was similar to those reported in convalescent sera taken from individuals 3–7 months following asymptomatic SARS-CoV-2 infection, and 2–3 years post-infection from symptomatic SARS-CoV-1 patients. HCoV-NL63 neutralising antibody titres decreased with increasing age (R2 = 0.042, p = 0.038), but did not differ by sex. Overall, this study demonstrates that neutralising antibody to HCoV-NL63 is detectable in approximately 71% of the healthy adult population of Australia. Similar titres did not impede the use of another seasonal human coronavirus (HCoV-229E) in a human challenge model, thus, HCoV-NL63 may be useful as a human challenge model for more pathogenic coronaviruses.

show abstract

“…Cross-reactivity with seasonal coronaviruses has to be considered. Even if recently, pre-existing HCoV-NL63 antibody response crossreacting with some SARS-CoV-2 antigens was detected in both pre-and mid-pandemic infected individuals [28], though no cross-reactivity of serology methods with the seasonal coronavirus was reported [29] and no neutralizing activity of SARS-CoV-2 in pre-pandemic sera was observed [30]. All IgT-positive serum samples were positive for antibodies against the RBD of S protein (Biosynex COVID19 BSS).…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France

Petit

Jeulin

Legrand

et al. 2021

Viruses

View full text Add to dashboard Cite

The World Health Organisation recommends monitoring the circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated anti–SARS-CoV-2 total immunoglobulin (IgT) antibody seroprevalence and in vitro sero-neutralization in Nancy, France, in spring 2020. Individuals were randomly sampled from electoral lists and invited with household members over 5 years old to be tested for anti–SARS-CoV-2 (IgT, i.e., IgA/IgG/IgM) antibodies by ELISA (Bio-rad); the sero-neutralization activity was evaluated on Vero CCL-81 cells. Among 2006 individuals, the raw seroprevalence was 2.1% (95% confidence interval 1.5 to 2.9), was highest for 20- to 34-year-old participants (4.7% (2.3 to 8.4)), within than out of socially deprived area (2.5% vs. 1%, p = 0.02) and with than without intra-family infection (p < 10−6). Moreover, 25% of participants presented at least one COVID-19 symptom associated with SARS-CoV-2 positivity (p < 10−13), with highly discriminant anosmia or ageusia (odds ratio 27.8 [13.9 to 54.5]); 16.3% (6.8 to 30.7) of seropositive individuals were asymptomatic. Positive sero-neutralization was demonstrated in vitro for 31/43 seropositive subjects. Regarding the very low seroprevalence, a preventive effect of the lockdown in March 2020 can be assumed for the summer, but a second COVID-19 wave, as expected, could be subsequently observed in this poorly immunized population.

show abstract

HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic

Cited by 31 publications

References 33 publications

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia

Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France

Contact Info

Product

Resources

About